The economic burden of epilepsy is well recognized. However, empirical investigation establishing costs associated with the diagnosis and treatment of non-epileptic psychogenic seizures (NEPS) is lacking. We studied 20 patients with video/EEG monitoring-confirmed NEPS to determine the effect of definitive diagnosis and treatment on medical costs and utilization. A medical resource utilization questionnaire and inpatient medical chart review were employed to calculate utilization information. Medication usage, outpatient visits, emergency room admissions, and diagnostic testing over a 6-month pre-diagnosis and a 6-month post-diagnosis period were compared. There was an 84% average reduction in total seizure-related medical charges in the 6 months following NEPS diagnosis. Average diagnostic testing charges declined 76%, average medication charges decreased 69%, outpatient clinic visits declined 80%, and emergency room visits reduced by 97%. A majority of patients obtaining a definitive inpatient video/EEG-seizure-monitoring-confirmed NEPS diagnosis experience substantial reductions in health care utilization and dollar costs.
INTRODUCTION
Health care costs associated with the treatment of epilepsy approach $1.5 billion for a single cohort year'. Unfortunately, 5-25% of the 2 million persons treated yearly for epilepsy in the USA are estimated to have nonepileptic psychogenic seizures (NEPS)*. The lifetime dollar costs associated with undiagnosed NEPS may approximate the lifetime dollar costs associated with the treatment of intractable epilepsy which is about $100000 per patient'. Overall incidence of NEPS has been estimated at 300000 to 400000 lives within the USA alone3A. Lifetime dollars costs per patient cohort year for a NEPS group could range from $110 million to $920 million. To date, the economic impact of the diagnosis and treatment of nonepileptic psychogenic seizures (NEPS) has not been formally established within the US health care system. Early identification of NEPS is important given the potential for misdiagnosis, iatrogenic hazards (e.g. antiepilepsy chug treatment), and costly protracted medical treatment. NEPS can be suggested by clinical observation of the patient's typical paroxysmal event'. However, the clinician's predictive accuracy in identifying NEPS prior to inpatient video/EEG monitoring is approximately 50%*. NEPS diagnosis may be determined during single session outpatient ambulatory EEG. NEPS are typically experienced an average of 3 to 7 years prior to definitive diagnosis from video/EEG inpatient monitoring, suggesting less than optimal diagnostic yield from available outpatient evaluation5~9. Continuous video/EEG inpatient monitoring is the standard for definitive NEPS diagnosis, but only a small fraction of persons with NEPS receive such diagnostic assessment". The disparity between incidence of NEPS and the utilization of continuous F?. C. Martin et a/ video/EEG inpatient monitoring reflects the absence of empirically-based information demonstrating the costeffectiveness of inpatient video/EEG monitoring for the definitive diagnosis of NEPS. The specific aim of this investigation was to document changes in health care utilization patterns and costs in a sample of NEPS patients definitively diagnosed through inpatient video/EEG seizure monitoring.
MATERIALS AND METHODS
This investigation was performed at the University of Alabama at Birmingham (UAB) Epilepsy Center. The program is a tertiary referral center for the region and includes an epilepsy surgery program. Diagnostic facilities for epilepsy include intensive seizure monitoring with 24-hour continuous video/EEG monitoring, magnetic resonance imaging, single photon emission tomography, and neuropsychological testing. Study patients received their NEPS diagnosis while on the inpatient continuous video/EEG seizure monitoring unit. All patients recruited for the present study were over the age of 18 at the time of their NEPS diagnosis.
Patients included in this study were referred to the UAB inpatient video/EEG seizure monitoring unit by his or her family physician or neurologist. The diagnostic question was to identify seizure type or confirm suspicion of nonepileptic events. Patients were given the diagnosis of NEPS based on inpatient video/BEG seizure monitoring recording of at least one typical clinical event. Diagnosis of NEPS was determined by the attending epileptologist on the UAB seizure monitoring unit, based on the absence of electrographic activity immediately prior to or during a typical event (as defined by the patient and/or family members), atypical behavior, and no separate evidence to suggest the episodes were due to neurologic disorder, incapacitating or progressive medical illness, or cardiorespiratory problems. Ictal EEGs were filtered and reformatted in different montages in a careful search for epileptiform features. Attention was paid to whether seizure onset occurred during sleep or was provoked by environmental factors. The presence or absence of inter-ictal spikes or post-ictal EEG slowing was considered. In addition, all suspected NEPS patients received psychological evaluation as part of their diagnostic workup. The psychological evaluation consisted of standardized psychometric testing and a diagnostic interview with the patient and available family' '3 I*. Communication of NEPS diagnosis was provided by the Epilepsy Center treatment team, with primary responsibility for diagnostic communication to the patient by the attending physician. Each patient received feedback from the clinical psychologist regarding their diagnosis. Patients were assisted in obtaining outpatient psychiatric/mental health referrals in their home area.
Patients
We attempted to contact a series of 44 adult patients who were definitively diagnosed as having NEPS while at the UAB seizure monitoring unit. Patients were contacted between 6 and 8 months from the time of their hospital discharge. A total of 20 patients from this series volunteered to provide information on their health care utilization before and after definitive NEPS diagnosis. We were unable to contact 24 of these patients due to a number of issues including unlisted telephone numbers or change of address (11 patients), not retuming telephone messages (eight patients), or declined participation (four patients). One patient was deceased at time of telephone contact (unrelated medical condition).
No patient in the present sample had a history or electrophysiological evidence to indicate co-existing epilepsy. Patients were told that their participation was voluntary and that the information provided was confidential.
Establishment
of NEPS-related health care utilization variables and cost figures Dollar charges were tabulated for standard epilepsyrelated health care cost variables which included medication usage, outpatient clinic visits, standard diagnostic testing (EEG, magnetic resonance imaging (MRI), computerized tomography (CT)), laboratory testing (blood serum levels, AED levels), and emergency room visit charges'. Medication prices were estimated by contacting three area pharmacies and obtaining price quotes on several standard antiepileptic medications. Medication charges were calculated by averaging the three price quotes. Outpatient clinic charges (physician charges and facility charges) were established through price quotes obtained from the UAB Outpatient Clinic administrative office. Diagnostic testing and emergency room charges were determined from information obtained through the UAB hospital business administrative office. Diagnostic testing charges included facility fees and physician charges. Emergency room charges were based upon estimates from a sample of 10 emergency room admissions for seizures (not including status epilepticus diagnosis) that had occurred over the past 6 months at our university hospital.
Health care utilization rates were requested for the 6-month time period preceding inpatient video/EEG seizure monitoring and the 6-month period immedi-health care resource utilization following confirmed diagnosis of NEPS 387 ately following definitive NEPS diagnosis. All 20 patients agreed to be interviewed and complete a health care utilization survey (adapted from WaIzack et al. 13). Health care utilization rates were established by patient self-report. We requested the same information from an available family member who was in the household (usually a spouse or parent). When there were discrepancies in the information from patient and family member we used the lower utilization of the two reports.
In addition, the hospital chart was reviewed at the time of inpatient seizure monitoring. Notation was made regarding information pertaining to recent provision of seizure-related medical services and medication regime.
RESULTS

Inpatient video/EEG monitoring costs
Average inpatient length of stay for the 20 NEPS study patients was 3.1 days (SE = 0.40, range = l-8 days, median days = 3.0). This is consistent with previous data from our center on average length of stay for NEPS patients, which was 2.5 days14. The average charge for hospitalization was $6832 (SE = 794.50; range = 1640-13 760; median = 7200). Total charges for the 20 patients were $136 640.
Demographic information
The final sample consisted of 14 females and 6 males (mean age = 36.8 years, range = 19-55). This is comparable to gender distributions reported in previous studies which demonstrate female preponderance', t5. Average duration of NEPS in this sample was 6.8 years (range = 6 months-33 years) with 60% of the sample experiencing NEPS for at least 3 years. Eighty-five percent of the sample were married (17/20), one patient was single, one patient was divorced, and one patient was separated at time of the inpatient monitoring. Employment status prior to inpatient monitoring was as follows: fulltime employed (2/20, lo%), not in work force (9/20,45%), receiving medical disability benefits for seizure disorder (4120, 20%) and employed but on medical leave at time of assessment (5/20,25%). At 6 months following NEPS diagnosis, three patients were employed fulltime (15%), two were part-time employed (10%) and six patients remained unemployed (30%). Six patients were receiving disability payments (30%), and two patients remained on medical leave (10%). Overall, at time of post-diagnostic interview four patients had gone from medical leave to full/part-time employment or from part-time to fulltime employment. Two patients had begun receiving disability benefits by 6 months postdiagnosis. No employment category shift was present in 12 of the patients.
Six of the recruited NEPS patients presented with histories of psychiatric diagnosis at time of inpatient video/EEG seizure monitoring (three with major depression, one with bipolar disorder, one with dysthymia, and one with polysubstance abuse). At the time of hospital discharge all NEPS patients had received a psychiatric diagnosis (DSM-IV classification").
The diagnosis of conversion disorder or somatoform disorder (not otherwise specified) was most often present while major depression, post-traumatic stress disorder, dissociative disorder (not otherwise specified), panic disorder, and borderline personality disorder were also psychiatric conditions diagnosed. Thirteen patients (65%) were receiving psychiatric/psychological intervention at 6 months following NEPS diagnosis.
In order to determine if the study NEPS patient sample was representative of the typical NEPS patient we evaluate, we compared the 24 nonparticipating NEPS patients from the recruitment series to the 20 study patients across several clinical and demographic features. The two groups did not differ for number of inpatient hospital days [r(44) = 0.56, NS]. The average length of stay for the nonparticipating NEPS patient was 2.8 days (SD = 1.5, range l-7 days, median = 3 days). Groups did not differ in terms of age , and all received DSM-IV diagnostic classification at the time of discharge similar in classification to the study patients (conversion disorder, major depression, etc.).
At the time of NEPS diagnosis, all 20 study patients were experiencing seizure frequency in the poorly controlled classification (p 12 major seizures per year, or 21 minor seizure per day)16. Previous research has shown that persons with poorly controlled seizures consume a disproportionate share of total treatment dollar costs compared with moderately controlled and well controlled seizure patients'. The NEPS patient group experienced an overall 69% decline in seizure frequency following seizure-monitoring-confirmed diagnosis. Twelve patients reported experiencing at least 90% reduction in NRPS frequency in the 6 months following their diagnosis. A Wilcoxon Rank Sums ANOVAl revealed a statistically significant decline in seizure frequency following NEPS diagnosis (z = 3.5, p < 0.0004). No patient reported an increased NEPS frequency following diagnosis. Ten of the 20 (50%) patients were no longer taking any antiepileptic medication, while six were either taking only one epileptic medication or lower dosages of prior seizure medications. One patient had been switched to another type of seizure medication by his primary care physician, and one other patient was not taking antiepileptic medication prior to NEPS diagnosis.
Health care utilization and charge figures
Health care utilization rates for our NEPS sample are presented (see Table 1 ). Overall, declines were observed across the post-diagnostic 6 month time period for the number of outpatient physician clinic visits, diagnostic procedures, laboratory tests, and, most significantly, the number of emergency room visits. Outpatient clinic visits declined by an average of 80% (range = O-100%; median value = 95%; Wilcoxon test: z = 3.8, p < 0.0001). The number of diagnostic procedures performed declined from a total of 55 procedures pre-diagnosis, to 14 procedures postdiagnosis (Wilcoxon test: z = 3.5, p < 0.0004). Laboratory testing declined by 80% (Wilcoxon test, z = 3.1, p c 0.002). Also emergency room visits dropped dramatically from a total of 123 visits prediagnosis to only four visits post-NEPS diagnosis (97% reduction; Wilcoxon test: z = 3.4, p c 0.0007). Table 2 presents the change in average billable charges for the 6 months before and 6 months after NEPS diagnosis. There was an 84% average reduction in total medical charges (medication charges, outpatient physician charges, emergency room charges, diagnostic procedure charges, and laboratory testing charges). Average dollar charges per patient went from $8156 (SE = $1649) to $1306 (SE = $440) (paired c test, r(l9) = 5.1, p < 0.003). Breakdown of charges by category can be seen in Table 2 . Significant decline of 97% was seen in terms of dollar charges for emergency room visits (f(l9) = 3.3, p < 0.004). Medication dollar charges declined significantly by 69% (t( 19) = 3.4, p < 0.003), while diagnostic testing charges declined by an average of 76% (t (19) = 5.2, p < 0.0001).
DISCUSSION
This study investigated health care utilization patterns in patients diagnosed with NEPS following inpatient video/EEG seizure monitoring. The data obtained on the cost/utilization figures in our sample of NEPS patients revealed substantial changes in medical costs and utilization rates following multidiscipIinary assessment and continuous video/EEG inpatient seizure monitoring. Specifically, downward shifts of greater than 70% were consistently seen across multiple utilization categories including emergency room visits and outpatient clinic visits. Significant dollar costs reductions were also observed. This information has important consequences as managed care begins altering the allocation of ever-tightening monetary resources to manage patients with epilepsy. Early identification of NEPS can ultimately help alleviate the financial drain to an already overwhelmed epilepsy clinical practice while initiating appropriate treatment care for NEPS populations.
Certainly, the treatment costs of undiagnosed NEPS patients would not be as high for every 6-month period, especially for diagnostic procedures. Many NEPS patients were referred for inpatient assessment onfy ufter extensive outpatient diagnostic examinations had been petjiormed (e.g. MRI scanning, repeated ambula-health care resource utilization following confirmed diagnosis of NEPS 389 tory EEG monitoring). It seems reasonable to assume that medication cost would remain steady, as would frequency of ambulatory care visits, outpatient clinic visits and laboratory work over an extended period of time. This would be the expected standard of care for intractable epilepsy patients. The long-term financial value of inpatient video/EEG monitoring is in the ability to make a definitive diagnosis. While immediate costs for inpatient assessment are not minor (average charges per inpatient evaluation were $6800) longterm charges (minus diagnostic testing) over a 6-year period (average duration of NEPS prior to diagnosis) could exceed $25 000 per patient. This figure represents the combined average charges of outpatient visits, medications, laboratory/serum work, and emergency room visits based upon estimates from our patient sample. Multiply this figure by annual incidence of NEPS3," and the summated dollar costs are considerable (e.g. $25 000 x 100 000400 000 patients = $2.5-10 billion dollars). Our sample consisted of 20 patients deemed to have poorly controlled paroxysmal events. In the epilepsy literature, this group of 'poorly controlled seizures' patients is by far the costliest in terms of direct and indirect costs'. Patients with intractable epilepsy, defined as severe, frequent, and not responsive to multiple medication trials, made up 15% of their incidence group, but over 50% of the direct costs of treatment. This information indicates that NEPS patients, prior to definitive diagnosis, are similar in terms of medical utilization and dollar costs to persons with severe intractable epilepsy.
NEPS is a diagnosable, although not easily identifiable, psychiatric condition commonly seen in general neurology outpatient practice6. Research has repeatedly demonstrated the critical importance of inpatient video/EEG seizure monitoring in the definitive diagnosis of this condition99 lg. The importance of video/EEG seizure monitoring is well established when related to appropriate diagnosis. With definitive diagnosis a dramatic shift of treatment modalities (e.g. antidepressant medication, psychotherapy) can be initiated which focus upon the more psychological/emotional aspects of the condition '*. Furthermore, research has demonstrated the long-term cost-effectiveness of mental health care within the broader medical managed care domain'9,20.
Certainly, definitive statements regarding the costeffectiveness of early video/EEG-seizure-monitoringbased diagnosis of NEPS cannot be elicited from this small sample group. However, this study was intended to document the potential for cost savings in a patient group that utilizes medical resources at high rates. More sophisticated prospective investigations employing cost-effectiveness analysis will certainly need to be pet-formed*'. In addition, beyond documenting cost savings within the epilepsy community, this type of analysis should lead to the development of decision models for determining when inpatient video/EEG seizure monitoring is the most cost-effective technology for the diagnosis and treatment of NEPS. The extent to which successful management of NEPS leads to changes in nonNEPS health care resource use should also be analyzed. Finally, outcomes of care, including Quality of Life, should be assessed and included in the analysis.
